Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.creator | Martin-Romano, P. (Patricia) | - |
dc.creator | Baraibar-Argota, I. (Iosune) | - |
dc.creator | Espinos, J. (Jaime) | - |
dc.creator | Legaspi, J. (Jairo) | - |
dc.creator | Lopez-Picazo, J.M. (José M.) | - |
dc.creator | Aramendia, J.M. (J.M.) | - |
dc.creator | Fernández, Ó.A. (Óscar A.) | - |
dc.creator | Santisteban, M. (Marta) | - |
dc.date.accessioned | 2024-02-01T13:49:51Z | - |
dc.date.available | 2024-02-01T13:49:51Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Martin-Romano, P. (Patricia); Baraibar-Argota, I. (Iosune); Espinos, J. (Jaime); et al. "Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience". The Breast Journal. 24 (4), 2017, 473 - 479 | es_ES |
dc.identifier.issn | 1524-4741 | - |
dc.identifier.uri | https://hdl.handle.net/10171/68709 | - |
dc.description.abstract | The combination of Pegylated Liposomal Doxorubicin (PLD) plus Gemcitabine (GEM) has been previously investigated in the treatment of metastatic breast cancer (MBC). PLD is a doxorubicin formulation with prolonged circulation time and better tissue distribution. GEM is a nucleoside analog with nonoverlapping toxicity compared to PLD. The aim of our study was to assess efficacy, toxicity, and long-term outcome of this combination. Patients with heavily treated MBC were retrospectively analyzed. Chemotherapy consisted of PLD 25 mg/m2 and GEM 800 mg/m2 day 1, on a three-week schedule. Cardiac function was evaluated baseline and during treatment. Radiological response was graded according to RECIST criteria v1.1. Toxicity was scored according to CTCAE v4.0. Progression-free survival (PFS) and overall survival (OS) were evaluated. From 2001 to 2014, 122 pts were included. Median age was 55 (range: 28-84). Median previous treatment schedules in the metastatic scenario were 3 (range: 1-15). Most patients received prior anthracyclines (85%). Median number of metastatic sites was 2 (range: 1-7). Median number of cycles delivered was 5 (range: 1-36). Overall response rate was 31% (5% complete responses; 26% partial responses). Stable and progressive diseases were observed in 32% and 26% of patients. Grade ≥3 neutropenia was observed in 29 patients (24%). Grade ≥3 hand-foot syndrome was detected in 17 patients (14%), mostly since cycle 3 (88%). Median cumulative PLD dose was 125 mg/m2. At a median follow-up of 101 months, median PFS and OS were 7 and 22 months, respectively. PLD-GEM combination achieves remarkable long-term outcomes with an acceptable toxicity profile in patients with MBC. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | info:eu-repo/semantics/closedAccess | es_ES |
dc.subject | Chemotherapy combination | es_ES |
dc.subject | Gemcitabine | es_ES |
dc.subject | Metastatic breast cancer | es_ES |
dc.subject | Pegylated liposomal doxorubicin | es_ES |
dc.title | Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1111/tbj.12975 | - |
dadun.citation.endingPage | 479 | es_ES |
dadun.citation.number | 4 | es_ES |
dadun.citation.publicationName | The Breast Journal | es_ES |
dadun.citation.startingPage | 473 | es_ES |
dadun.citation.volume | 24 | es_ES |
dc.identifier.pmid | 29286192 | - |
Ficheros en este ítem:
Estadísticas e impacto
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.